(Reuters) - U.S. health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhea in HIV/AIDS patients on antiretroviral therapy, a combination of medicines used to treat HIV infection.
Diarrhea is a common reason why HIV/AIDS patients discontinue or switch their antiretroviral therapies.
The drug, called Fulyzaq, is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite.
Until now, there have been no therapies for HIV-associated diarrhea approved by the U.S. Food and Drug Administration.
Diarrhea is a common reason why HIV/AIDS patients discontinue or switch their antiretroviral therapies.
The drug, called Fulyzaq, is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite.
Until now, there have been no therapies for HIV-associated diarrhea approved by the U.S. Food and Drug Administration.
FDA approves Salix's diarrhea drug for HIV/AIDS patients
This article
FDA approves Salix's diarrhea drug for HIV/AIDS patients
can be opened in url
http://newspolitiics.blogspot.com/2013/01/fda-approves-salixs-diarrhea-drug-for.html
FDA approves Salix's diarrhea drug for HIV/AIDS patients
